.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,422,368

« Back to Dashboard

Claims for Patent: 5,422,368

Title: Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
Abstract:The invention relates to ophthalmological compositions for topical treatment of glaucoma or ocular hypertension comprising an effective intraocular pressure reducing amount of a prostaglandin derivative of PGA, PGB, PGD, PGE or PGF, in which the omega chain contains a ring structure, in an ophthalmologically compatible carrier. The invention further relates to the preparation of said compositions and their use for treatment of glaucoma or ocular hypertension.
Inventor(s): Stjernschantz; Johan W. (Upsala, SE), Resul; Bahram (Upsala, SE)
Assignee: Kabi Pharmacia AB (Upsala, SE)
Application Number:07/986,943
Patent Claims: 1. A therapeutic composition for topical treatment of ocular hypertension or glaucoma containing a prostaglandin PGA, PGB, PGE or PGF in an amount sufficient to reduce intraocular pressure without causing substantial ocular irritation, and an ophthalmologically compatible vehicle, in which the alpha chain of the prostaglandin comprises a chain of 6 to 10 carbon atoms, which is either

(a) saturated or

(b) unsaturated having one or more double bonds, allene bonds, or a triple bond,

the alpha chain being

(c) unsubstituted or

(d) substituted with one or more substituents selected from the group of alkyl groups, alicyclic rings, aromatic rings or heteroaromatic rings,

and in which the omega chain of the prostaglandin has the formula

wherein

C is a carbon atom (the number according to standard prostaglandin nomenclature being indicated by the subscript);

B is a single bond, a double bond, or a triple bond;

D represents a sub-chain of 1-10 carbon atoms with substituents on each carbon atom that are selected from the group consisting of a hydrogen atom, an alkyl group, an oxo group and a hydroxyl group, and

R.sub.2 is

(e) an aromatic ring structure which is

(1) unsubstituted or

(2) has at least one substituent selected from the group consisting of

C.sub.1 -C.sub.5 alkyl groups,

C.sub.1 -C.sub.4 alkoxy groups,

trifluoromethyl groups,

C.sub.1 -C.sub.3 aliphatic acylamino groups,

nitro groups,

halogen atoms,

a phenyl group, or

(f) an aromatic heterocyclic group having 5-6 ring atoms, or

(g) a cycloalkane or a cycloalkene with 3-7 carbon atoms in the ring, which is

(1) unsubstituted or

(2) has at least one substituent selected from the group consisting of lower alkyl groups with 1-5 carbon atoms.

2. A composition according to claim 1 in which, in the omega chain of the prostaglandin, R.sub.2 is an aromatic ring structure which is

(1) unsubstituted or

(2) has at least one substituent selected from the group consisting of

C.sub.1 -C.sub.5 alkyl groups,

C.sub.1 -C.sub.4 alkoxy groups,

trifluoromethyl groups,

C.sub.1 -C.sub.3 aliphatic acylamino groups,

nitro groups,

halogen atoms, or

a phenyl group.

3. A composition according to claim 1 in which, in the omega chain of the prostaglandin, R.sub.2 is a phenyl group which is

(1) unsubstituted or

(2) has at least one substituent selected from the group consisting of

C.sub.1 -C.sub.5 alkyl groups,

C.sub.1 -C.sub.4 alkoxy groups,

trifluoromethyl groups,

C.sub.1 -C.sub.3 aliphatic acylamino groups,

nitro groups,

halogen atoms, or

a phenyl group.

4. A composition according to claim 1 in which, in the omega chain of the prostaglandin R.sub.2 is a phenyl group.

5. A composition according to claim 1 in which, in the omega chain of the prostaglandin PGA, PGB, PGE, or PGF, the D sub-chain contains 2-8 carbon atoms.

6. A composition according to claim 1 in which, in the omega chain of the prostaglandin, the D sub-chain contains 2-5 carbon atoms.

7. A composition according to claim 6 in which the prostaglandin is a PGF.sub.2.alpha..

8. A composition according to claim 7 in which, in the omega chain of the prostaglandin,

B is a single bond;

D is a chain of 3 carbon atoms; and

R.sub.2 is a phenyl group.

9. A composition according to claim 1 in which, in the omega chain of the prostaglandin, the D sub-chain contains 3 carbon atoms.

10. A composition according to claim 1 in which the prostaglandin is a PGA.sub.2, PGB.sub.2, PGE.sub.2 or PGF.sub.2.

11. A composition according to claim 1 in which, in the omega chain of the prostaglandin,

B is a single or double bond,

D is a carbon chain with 2-5 carbon atoms, in which C.sub.15 is substituted with an oxo or hydroxyl substitutent, and C.sub.16 -C.sub.19 are unsubstituted or substituted with lower alkyl substituents, and

R.sub.2 is a phenyl ring which is unsubstituted or substituted with one or more substituent selected from the group consisting of alkyl or alkoxy groups.

12. A composition according to claim 1 in which the prostaglandin is a PGE.

13. A composition according to claim 1 in which the prostaglandin is a PGF.

14. A composition according to claim 1 in which the prostaglandin is a PGF.sub.2.

15. A composition according to claim 1 in which, in the omega chain of the prostaglandin,

B is a single or double bond;

D is a chain of 3 carbon atoms; and

R.sub.2 is a phenyl group.

16. A composition according to claim 1 in which, in the omega chain of the prostaglandin,

B is a single bond;

D is a chain of 3 carbon atoms; and

R.sub.2 is a phenyl group.

17. A composition according to claim 1 in which, in the omega chain of the prostaglandin,

B is a single bond;

D is a chain of 3 carbon atoms, in which C.sub.15 is substituted with an oxo group, an (R)--OH group, or an (S)--OH group; and

R.sub.2 is a phenyl group.

18. A composition according to claim 1 in which, in the omega chain of the prostaglandin,

B is a single bond;

D is a chain of 3 carbon atoms, in which C.sub.15 is substituted with an oxo group; and

R.sub.2 is a phenyl group.

19. A composition according to claim 1 in which the prostaglandin is an isopropyl ester.

20. A composition according to claim 1 in which the prostaglandin is an ester of 13,14-dihydro-17-phenyl-18,19,20-trinor-PGF.sub.2.alpha..

21. A composition according to claim 1 in which the prostaglandin is an alkyl ester of 13,14-dihydro-17-phenyl-18,19,20-trinor-PGF.sub.2.alpha., having 1-10 carbon atoms in the alkyl group.

22. A composition according to claim 1 in which the prostaglandin is 13,14-dihydro-17-phenyl-18,19,20-trinor-PGF.sub.2.alpha. isopropyl ester.

23. A composition according to claim 1 in which the prostaglandin is 13,14-dihydro-17-phenyl-18,19,20-trinor-PGF.sub.2.alpha..

24. A method of treating glaucoma or ocular hypertension by topical application of the therapeutic composition of claim 1.

25. The method of claim 23 in which the composition of claim 1 is applied once or twice a day.

26. The method of claim 23 wherein the composition applied contains from about 0.1 .mu.g to about 30 .mu.g of the prostaglandin.

27. The method of claim 23 wherein the composition applied contains about 1.0 .mu.g to about 10 .mu.g of the prostaglandin.

28. The method of claim 23 wherein the composition is applied twice a day, containing about 1.0 .mu.g to about 10 .mu.g of prostaglandin in a volume of about 10 to about 50 .mu.L of composition.

29. A therapeutic composition for topical treatment of ocular hypertension or glaucoma containing a prostaglandin PGA, PGB, PGE or PGF in an amount sufficient to reduce intraocular pressure without causing substantial ocular irritation, and an ophthalmologically compatible vehicle, in which the alpha chain of the prostaglandin comprises a chain of 6 to 10 carbon atoms, which is either

(a) saturated or

(b) unsaturated having one or more non-cummulated double bonds, or a triple bond,

the alpha chain being

(c) unsubstituted or

(d) substituted with one or more substituents selected from the group of alkyl groups, alicyclic rings, aromatic rings or heteroaromatic rings,

and in which the omega chain of the prostaglandin has the formula

wherein

C is a carbon atom (the number according to standard prostaglandin nomenclature being indicated by the subscript);

B is a single bond, a double bond, or a triple bond;

D represents a sub-chain of 1-10 carbon atoms and 1-2 heteroatoms selected from the group oxygen, sulfur, and nitrogen, with substituents on each carbon atom that are selected from the group consisting of a hydrogen atom, an alkyl group, an oxo group and a hydroxyl group, and

R.sub.2 is

(e) an aromatic ring structure which is

(1) unsubstituted or

(2) has at least one substituent selected from the group consisting of

C.sub.1 -C.sub.5 alkyl groups,

C.sub.1 -C.sub.4 alkoxy groups,

trifluoromethyl groups,

C.sub.1 -C.sub.3 aliphatic acylamino groups,

nitro groups,

halogen atoms,

a phenyl group, or

(f) an aromatic heterocyclic group having 5-6 ring atoms, or

(g) a cycloalkane or a cycloalkene with 3-7 carbon atoms in the ring, which is

(1) unsubstituted or

(2) has at least one substituent selected from the group consisting of lower alkyl groups with 1-5 carbon atoms.

30. A composition according to claim 28 in which, in the omega chain of the prostaglandin, R.sub.2 is an aromatic ring structure which is

(1) unsubstituted or

(2) has at least one substituent selected from the group consisting of

C.sub.1 -C.sub.5 alkyl groups,

C.sub.1 -C.sub.4 alkoxy groups,

trifluoromethyl groups,

C.sub.1 -C.sub.3 aliphatic acylamino groups,

nitro groups,

halogen atoms, or

a phenyl group.

31. A composition according to claim 28 in which, in the omega chain of the prostaglandin, R.sub.2 is a phenyl group which is

(1) unsubstituted or

(2) has at least one substituent selected from the group consisting of

C.sub.1 -C.sub.5 alkyl groups,

C.sub.1 -C.sub.4 alkoxy groups,

trifluoromethyl groups,

C.sub.1 -C.sub.3 aliphatic acylamino groups,

nitro groups,

halogen atoms, or

a phenyl group.

32. A composition according to claim 28 in which, in the omega chain of the prostaglandin R.sub.2 is a cycloalkane or a cycloalkene with 3-7 carbon atoms in the ring, which is

(1) unsubstituted or

(2) has at least one substituent selected from the group consisting of lower alkyl groups with 1-5 carbon atoms.

33. A composition according to claim 28 in which, in the omega chain of the prostaglandin PGA, PGB, PGE, or PGF, the D sub-chain contains 2-8 carbon atoms.

34. A composition according to claim 28 in which, in the omega chain of the prostaglandin, the D sub-chain contains 2-5 carbon atoms.

35. A composition according to claim 33 in which the prostaglandin is a PGF.sub.2.alpha..

36. A composition according to claim 34 in which, in the omega chain of the prostaglandin,

B is a single bond;

D is a chain of 3 carbon atoms; and

R.sub.2 is a phenyl group.

37. A composition according to claim 28 in which, in the omega chain of the prostaglandin, the D sub-chain contains 3 carbon atoms.

38. A composition according to claim 28 in which the prostaglandin is a PGA.sub.2, PGB.sub.2, PGE.sub.2 or PGF.sub.2.

39. A composition according to claim 28 in which, in the omega chain of the prostaglandin,

B is a single or double bond,

D is a carbon chain with 2-5 carbon atoms, in which C.sub.15 is substituted with an oxo or hydroxyl substitutent, and C.sub.16 -C.sub.19 are unsubstituted or substituted with lower alkyl substituents, and

R.sub.2 is a phenyl ring which is unsubstituted or substituted with one or more subsitutent selected from the group consisting of alkyl or alkoxy groups.

40. A composition according to claim 28 in which the prostaglandin is a PGE.

41. A composition according to claim 28 in which the prostaglandin is a PGF.

42. A composition according to claim 28 in which the prostaglandin is a PGF.sub.2.

43. A composition according to claim 28 in which, in the omega chain of the prostaglandin,

B is a single or double bond;

D is a chain of 3 carbon atoms; and

R.sub.2 is a phenyl group.

44. A composition according to claim 28 in which, in the omega chain of the prostaglandin,

B is a single bond;

D is a chain of 3 carbon atoms; and

R.sub.2 is a phenyl group.

45. A composition according to claim 28 in which, in the omega chain of the prostaglandin,

B is a single bond;

D is a chain of 3 carbon atoms, in which C.sub.15 is substituted with an oxo group, an (R)--OH group, or an (S)--OH group; and

R.sub.2 is a phenyl group.

46. A composition according to claim 28 in which, in the omega chain of the prostaglandin,

B is a single bond;

D is a chain of 3 carbon atoms, in which C.sub.15 is substituted with an oxo group; and

R.sub.2 is a phenyl group.

47. A composition according to claim 28 in which the prostaglandin is an isopropyl ester.

48. A composition according to claim 28 in which the prostaglandin is an ester of 13,14-dihydro-17-phenyl-18,19,20-trinor-PGF.sub.2.alpha..

49. A composition according to claim 28 in which the prostaglandin is an alkyl ester of 13,14-dihydro-17-phenyl-18,19,20-trinor-PGF.sub.2.alpha., having 1-10 carbon atoms in the alkyl group.

50. A composition according to claim 28 in which the prostaglandin is 13,14-dihydro-17-phenyl-18,19,20-trinor-PGF.sub.2.alpha. isopropyl ester.

51. A composition according to claim 28 in which the prostaglandin is 13,14-dihydro-17-phenyl-18,19,20-trinor-PGF.sub.2.alpha..

52. A method of treating glaucoma or ocular hypertension by topical application of the therapeutic composition of claim 28.

53. The method of claim 51 in which the composition of claim 49 is applied once or twice a day.

54. The method of claim 51 wherein the composition applied contains from about 0.1 .mu.g to about 30 .mu.g of the prostaglandin.

55. The method of claim 51 wherein the composition applied contains about 1.0 .mu.g to about 10 .mu.g of the prostaglandin.

56. The method of claim 51 wherein the composition is applied twice a day, containing about 1.0 .mu.g to about 10 .mu.g of prostaglandin in a volume of about 10 to about 50 .mu.L of composition.

57. A therapeutic composition for topical treatment of ocular hypertension or glaucoma containing a prostaglandin PGD in an amount sufficient to reduce intraocular pressure without causing substantial ocular irritation, and an ophthalmologically compatible vehicle, in which the alpha chain of the prostaglandin comprises a chain of 6 to 10 carbon atoms, which is either

(a) saturated or

(b) unsaturated having one or more double bonds, allene bonds, or a triple bond,

the alpha chain being

(c) unsubstituted or

(d) substituted with one or more substituents selected from the group of alkyl groups, alicyclic rings, aromatic rings or heteroaromatic rings,

and in which the omega chain of the prostaglandin has the formula

wherein

C is a carbon atom (the number according to standard prostaglandin nomenclature being indicated by the subscript);

B is a single bond, a double bond, or a triple bond;

D represents a sub-chain of 1-10 carbon atoms with substituents on each carbon atom that are selected from the group consisting of a hydrogen atom, an alkyl group, an oxo group and a hydroxyl group, and

R.sub.2 is

(e) an aromatic ring structure which is

(1) unsubstituted or

(2) has at least one substituent selected from the group consisting of

C.sub.1 -C.sub.5 alkyl groups,

C.sub.1 -C.sub.4 alkoxy groups,

trifluoromethyl groups,

C.sub.1 -C.sub.3 aliphatic acylamino groups,

nitro groups,

halogen atoms,

a phenyl group, or

(f) an aromatic heterocyclic group having 5-6 ring atoms.

58. A composition according to claim 56 in which, in the omega chain of the prostaglandin, R.sub.2 is an aromatic ring structure which is

(1) unsubstituted or

(2) has at least one substituent selected from the group consisting of

C.sub.1 -C.sub.5 alkyl groups,

C.sub.1 -C.sub.4 alkoxy groups,

trifluoromethyl groups,

C.sub.1 -C.sub.3 aliphatic acylamino groups,

nitro groups,

halogen atoms, or

a phenyl group.

59. A composition according to claim 56 in which, in the omega chain of the prostaglandin, R.sub.2 is a phenyl group which is

(1) unsubstituted or

(2) has at least one substituent selected from the group consisting of

C.sub.1 -C.sub.5 alkyl groups,

C.sub.1 -C.sub.4 alkoxy groups,

trifluoromethyl groups,

C.sub.1 -C.sub.3 aliphatic acylamino groups,

nitro groups,

halogen atoms, or

a phenyl group.

60. A composition according to claim 58 in which, in the omega chain of the prostaglandin the group R.sub.2 is thiazol, imidazole, pyrrolidine, thiophene or oxazole.

61. A composition according to claim 56 in which, in the omega chain of the prostaglandin PGD, the D sub-chain contains 2-8 carbon atoms.

62. A composition according to claim 56 in which, in the omega chain of the prostaglandin, the D sub-chain contains 2-5 carbon atoms.

63. A composition according to claim 61 in which, in the omega chain of the prostaglandin,

B is a single bond;

D is a chain of 3 carbon atoms; and

R.sub.2 is a phenyl group.

64. A composition according to claim 56 in which, in the omega chain of the prostaglandin, the D sub-chain contains 3 carbon atoms.

65. A composition according to claim 56 in which, in the omega chain of the prostaglandin,

B is a single or double bond,

D is a carbon chain with 2-5 carbon atoms, in which C.sub.15 is substituted with an oxo or hydroxyl substitutent, and C.sub.16 -C.sub.19 are unsubstituted or substituted with lower alkyl substituents, and

R.sub.2 is a phenyl ring which is unsubstituted or substituted with one or more subsitutent selected from the group consisting of alkyl or alkoxy groups.

66. A composition according to claim 56 in which, in the omega chain of the prostaglandin,

B is a single or double bond;

D is a chain of 3 carbon atoms; and

R.sub.2 is a phenyl group.

67. A composition according to claim 56 in which, in the omega chain of the prostaglandin,

B is a single bond;

D is a chain of 3 carbon atoms; and

R.sub.2 is a phenyl group.

68. A composition according to claim 56 in which, in the omega chain of the prostaglandin,

B is a single bond;

D is a chain of 3 carbon atoms, in which C.sub.15 is substituted with an oxo group, an (R)--OH group or an (S)--OH group; and

R.sub.2 is a phenyl group.

69. A composition according to claim 56 in which, in the omega chain of the prostaglandin,

B is a single bond;

D is a chain of 3 carbon atoms, in which C.sub.15 is a carbonyl group; and

R.sub.2 is a phenyl group.

70. A composition according to claim 56 in which the prostaglandin is an isopropyl ester.

71. A method of treating glaucoma or ocular hypertension by topical application of the therapeutic composition of claim 56.

72. The method of claim 71 in which the composition of claim 56 is applied once or twice a day.

73. The method of claim 71 wherein the composition applied contains from about 0.1 .mu.g to about 30 .mu.g of the prostaglandin.

74. The method of claim 71 wherein the composition applied contains about 1.0 .mu.g to about 10 .mu.g of the prostaglandin.

75. The method of claim 71 wherein the composition is applied twice a day, containing about 1.0 .mu.g to about 10 .mu.g of prostaglandin in a volume of about 10 to about 50 .mu.L of composition.

76. A composition according to claim 28 in which the D sub-chain contains 3 carbon atoms and the R.sub.2 group of the prostaglandin is located at position 17.

77. A composition according to claim 25 in which the D sub-chain contains 3 carbon atoms and the R.sub.2 group of the prostaglandin is located at position 17.

78. A composition according to claim 26 in which the D sub-chain contains 3 carbon atoms and the R.sub.2 group of the prostaglandin is located at position 17.

79. A method of treating glaucoma or ocular hypertension by topical application of the therapeutic composition of claim 76.

80. A method of treating glaucoma or ocular hypertension by topical application of the therapeutic composition of claim 77.

81. A method of treating glaucoma or ocular hypertension by topical application of the therapeutic composition of claim 78.

82. A composition according to claim 44 comprising a 13,14-dihydro-15-dehydro-17-phenyl-18,19,20-trinor-PGF2.alpha. alkyl ester having 1-10 carbon atoms in the alkyl group.

83. A composition according to claim 36 comprising a 13,14-dihydro-15-dehydro-17-phenyl-18,19,20-trinor-PGF2.alpha. alkyl ester having 1-10 carbon atoms in the alkyl group.

84. A composition according to claim 38 comprising a 13,14-dihydro-15-dehydro-17-phenyl-18,19,20-trinor-PGF2.alpha. alkyl ester having 1-10 carbon atoms in the alkyl group.

85. A method of treating glaucoma or ocular hyptertension by topical application of the therapeutic composition of claim 81.

86. A method of treating glaucoma or ocular hyptertension by topical application of the therapeutic composition of claim 82.

87. A method of treating glaucoma or ocular hyptertension by topical application of the therapeutic composition of claim 83.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc